ARTICLE | Company News

Tesaro submits NDA for oral rolapitant

September 9, 2014 2:14 AM UTC

Tesaro Inc. (NASDAQ:TSRO) submitted an NDA to FDA for oral rolapitant to prevent chemotherapy-induced nausea and vomiting (CINV). The company has exclusive, worldwide rights to the neurokinin 1 (NK1) Substance P receptor (TACR1) antagonist from Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK). ...